Lista de obras - Qing Ma - Dominio Público Uruguay

A Review of Clinical Pharmacokinetic and Pharmacodynamic Profiles of Select Antiretrovirals: Focus on Differences among Chinese Patients

scientific article published on 15 November 2019

Advances in pharmacogenomics of antiretrovirals: an update.

artículo científico publicado en 2007

Aspirin responsiveness changes in obese patients following bariatric surgery

artículo científico publicado en 2017

Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile.

artículo científico publicado en 2004

CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients

artículo científico publicado en 2010

Clinical application of the paraspinal erector approach for spinal canal decompression in upper lumber burst fractures

artículo científico publicado en 2014

Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals

artículo científico publicado en 2017

Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients.

artículo científico publicado en 2013

Comparative Tissue Factor Pathway Inhibitor Release Potential of Heparins

artículo científico publicado en 2005

Critical pathways: the role of pharmacy today and tomorrow.

artículo científico publicado en 2006

Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid

artículo científico publicado en 2018

Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies

artículo científico publicado en 2002

Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy

artículo científico publicado en 2014

Disulfiram metabolite S-methyl-N,N-diethylthiocarbamate quantitation in human plasma with reverse phase ultra performance liquid chromatography and mass spectrometry.

artículo científico publicado en 2012

Drug interactions between proton pump inhibitors and antiretroviral drugs.

artículo científico publicado en 2007

Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection

artículo científico publicado en 2015

Effect of rilpivirine on the pharmacokinetics of methadone in HIV-Infected Chinese patients

scientific article published on 15 May 2019

Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia

artículo científico publicado en 2009

Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population

artículo científico publicado en 2017

Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir

artículo científico publicado en 2007

Global Anticoagulant Effects of a Novel Sulfated Pentomanan Oligosaccharide Mixture

artículo científico publicado en 2001

Global HIV/AIDS Clinical and Translational Pharmacology

artículo científico publicado en 2012

Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.

artículo científico publicado en 2003

Host proteome research in HIV infection.

artículo científico publicado en 2010

Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.

artículo científico publicado en 2017

Influence of different anticoagulant agents on fibrinopeptide a generation

artículo científico publicado en 2003

Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist

artículo científico publicado en 2001

Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.

artículo científico publicado en 2007

Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism

scientific article published on 11 October 2013

Interactions Between Buprenorphine and the Protease Inhibitors Darunavir-Ritonavir and Fosamprenavir-Ritonavir ⬇️

artículo científico publicado el 18 de noviembre de 2011

Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.

artículo científico publicado en 2010

Molecular and biochemical profiling of a heparin-derived oligosaccharide, C3

artículo científico publicado en 2002

Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan

artículo científico publicado en 2004

Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides.

artículo científico publicado en 2006

Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.

artículo científico publicado en 2007

Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults

artículo científico publicado en 2012

Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

artículo científico publicado en 2013

Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice

artículo científico publicado en 2003

Pharmacodynamics and pharmacokinetics of C3, a heparin-derived oligosaccharide mixture, in non-human primates.

artículo científico publicado en 2003

Pharmacogenomics and HIV pharmacotherapy

article

Pharmacogenomics of CYP3A: considerations for HIV treatment

artículo científico publicado en 2009

Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications

artículo científico publicado en 2017

Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir

artículo científico publicado en 2010

Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients.

artículo científico publicado en 2013

Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals

artículo científico publicado en 2016

Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients

artículo científico publicado en 2005

Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans

artículo científico publicado en 2011

Pharmacologic approaches to the treatment of Huntington's disease

artículo científico publicado el 13 de octubre de 2011

Recent advances in management of the HIV/HCV coinfected patient

artículo científico publicado en 2015

Research in women and special populations

artículo científico publicado en 2008

Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.

artículo científico publicado en 2014

Single-tablet, once-daily treatment regimens for HIV.

artículo científico publicado en 2014

Studies on the effect of calcium in interactions between heparin and heparin cofactor II using surface plasmon resonance

artículo científico publicado en 2004

Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid

scientific article published on 27 September 2019

The blood-brain barrier accessibility of a heparin-derived oligosaccharides C3.

artículo científico publicado en 2002

The impact of herbal drug use on adverse drug reaction profiles of patients on antiretroviral therapy in zimbabwe

artículo científico publicado en 2012

Therapeutic drug monitoring in highly active antiretroviral therapy.

artículo científico publicado en 2010

Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.

artículo científico publicado en 2011

Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients

artículo científico publicado en 2010

Lista de obras de Qing Ma

A Review of Clinical Pharmacokinetic and Pharmacodynamic Profiles of Select Antiretrovirals: Focus on Differences among Chinese Patients

Advances in pharmacogenomics of antiretrovirals: an update.

Aspirin responsiveness changes in obese patients following bariatric surgery

Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile.

CYP2B6 polymorphism and nonnucleoside reverse transcriptase inhibitor plasma concentrations in Chinese HIV-infected patients

Clinical application of the paraspinal erector approach for spinal canal decompression in upper lumber burst fractures

Combination antiretroviral therapy improves cognitive performance and functional connectivity in treatment-naïve HIV-infected individuals

Comparative Effectiveness of Darunavir 1,200 mg Daily and Approved Dosing Strategies for Protease Inhibitor-Experienced Patients.

Comparative Tissue Factor Pathway Inhibitor Release Potential of Heparins

Critical pathways: the role of pharmacy today and tomorrow.

Development and validation of an LC-MS/MS assay for tenofovir and tenofovir alafenamide in human plasma and cerebrospinal fluid

Development of a non-human primate sub-clinical model of heparin-induced thrombocytopenia: platelet responses to human anti-heparin-platelet factor 4 antibodies

Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapy

Disulfiram metabolite S-methyl-N,N-diethylthiocarbamate quantitation in human plasma with reverse phase ultra performance liquid chromatography and mass spectrometry.

Drug interactions between proton pump inhibitors and antiretroviral drugs.

Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection

Effect of rilpivirine on the pharmacokinetics of methadone in HIV-Infected Chinese patients

Efficacy and safety of pegylated interferon alpha-2a therapy for chronic hepatitis C in HIV-infected patients with haemophilia

Evaluation of CYP2D6 phenotype in the Yoruba Nigerian population

Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavir

Global Anticoagulant Effects of a Novel Sulfated Pentomanan Oligosaccharide Mixture

Global HIV/AIDS Clinical and Translational Pharmacology

Global anticoagulant effects of a synthetic anti-factor Xa inhibitor (DX-9065a): implications for interventional use.

Host proteome research in HIV infection.

Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.

Influence of different anticoagulant agents on fibrinopeptide a generation

Inhibition of tissue factor-activated platelets by low-molecular-weight heparins and glycoprotein IIb/IIIa receptor antagonist

Interaction between buprenorphine and atazanavir or atazanavir/ritonavir.

Interaction of disulfiram with antiretroviral medications: efavirenz increases while atazanavir decreases disulfiram effect on enzymes of alcohol metabolism

Interactions Between Buprenorphine and the Protease Inhibitors Darunavir-Ritonavir and Fosamprenavir-Ritonavir ⬇️

Interactions between buprenorphine and antiretrovirals: nucleos(t)ide reverse transcriptase inhibitors (NRTI) didanosine, lamivudine, and tenofovir.

Molecular and biochemical profiling of a heparin-derived oligosaccharide, C3

Molecular and pharmacologic profile of tinzaparin and a comparable low-molecular-weight bacterial sulfaminoheparosan

Molecular weight dependent tissue factor pathway inhibitor release by heparin and heparin oligosaccharides.

Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV.

Nevirapine-Based Antiretroviral Therapy Impacts Artesunate and Dihydroartemisinin Disposition in HIV-Infected Nigerian Adults

Outcomes by sex following treatment initiation with atazanavir plus ritonavir or efavirenz with abacavir/lamivudine or tenofovir/emtricitabine.

Pharmacodynamic and pharmacokinetic properties of enoxaparin : implications for clinical practice

Pharmacodynamics and pharmacokinetics of C3, a heparin-derived oligosaccharide mixture, in non-human primates.

Pharmacogenomics and HIV pharmacotherapy

Pharmacogenomics of CYP3A: considerations for HIV treatment

Pharmacokinetic Considerations for Combining Antiretroviral Therapy, Direct-Acting Antiviral Agents for Hepatitis C Virus, and Addiction Treatment Medications

Pharmacokinetic interactions between buprenorphine/naloxone and once-daily lopinavir/ritonavir

Pharmacokinetic interactions of CEP-1347 and atazanavir in HIV-infected patients.

Pharmacokinetic, Pharmacogenetic, and Other Factors Influencing CNS Penetration of Antiretrovirals

Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients

Pharmacokinetics of the nonnucleoside reverse transcriptase inhibitor efavirenz among HIV-infected Ugandans

Pharmacologic approaches to the treatment of Huntington's disease

Recent advances in management of the HIV/HCV coinfected patient

Research in women and special populations

Sex differences in atazanavir pharmacokinetics and associations with time to clinical events: AIDS Clinical Trials Group Study A5202.

Single-tablet, once-daily treatment regimens for HIV.

Studies on the effect of calcium in interactions between heparin and heparin cofactor II using surface plasmon resonance

Switching to Tenofovir Alafenamide in Elvitegravir-Based Regimens: Pharmacokinetics and Antiviral Activity in Cerebrospinal Fluid

The blood-brain barrier accessibility of a heparin-derived oligosaccharides C3.

The impact of herbal drug use on adverse drug reaction profiles of patients on antiretroviral therapy in zimbabwe

Therapeutic drug monitoring in highly active antiretroviral therapy.

Therapeutic drug monitoring of protease inhibitors and efavirenz in HIV-infected individuals with active substance-related disorders.

Within-patient atazanavir trough concentration monitoring in HIV-1-infected patients